» Articles » PMID: 36225305

PGC-1α Activity and Mitochondrial Dysfunction in Preterm Infants

Overview
Journal Front Physiol
Date 2022 Oct 13
PMID 36225305
Authors
Affiliations
Soon will be listed here.
Abstract

Extremely low gestational age neonates (ELGANs) are born in a relatively hyperoxic environment with weak antioxidant defenses, placing them at high risk for mitochondrial dysfunction affecting multiple organ systems including the nervous, respiratory, ocular, and gastrointestinal systems. The brain and lungs are highly affected by mitochondrial dysfunction and dysregulation in the neonate, causing white matter injury (WMI) and bronchopulmonary dysplasia (BPD), respectively. Adequate mitochondrial function is important in providing sufficient energy for organ development as it relates to alveolarization and axonal myelination and decreasing oxidative stress via reactive oxygen species (ROS) and reactive nitrogen species (RNS) detoxification. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) is a master regulator of mitochondrial biogenesis and function. Since mitochondrial dysfunction is at the root of WMI and BPD pathobiology, exploring therapies that can regulate PGC-1α activity may be beneficial. This review article describes several promising therapeutic agents that can mitigate mitochondrial dysfunction through direct and indirect activation and upregulation of the PGC-1α pathway. Metformin, resveratrol, omega 3 fatty acids, montelukast, L-citrulline, and adiponectin are promising candidates that require further pre-clinical and clinical studies to understand their efficacy in decreasing the burden of disease from WMI and BPD in preterm infants.

Citing Articles

Predictive value of serum MED1 and PGC-1α for bronchopulmonary dysplasia in preterm infants.

Li M, Sun W, Fu C, Xu S, Wang C, Chen H BMC Pulm Med. 2024; 24(1):363.

PMID: 39069619 PMC: 11285520. DOI: 10.1186/s12890-024-03145-z.


Shikonin blocks CAF-induced TNBC metastasis by suppressing mitochondrial biogenesis through GSK-3β/NEDD4-1 mediated phosphorylation-dependent degradation of PGC-1α.

Fan S, Yan X, Hu X, Liu X, Zhao S, Zhang Y J Exp Clin Cancer Res. 2024; 43(1):180.

PMID: 38937832 PMC: 11210116. DOI: 10.1186/s13046-024-03101-z.


Melatonin as a Therapy for Preterm Brain Injury: What Is the Evidence?.

Hausler S, Robertson N, Golhen K, van den Anker J, Tucker K, Felder T Antioxidants (Basel). 2023; 12(8).

PMID: 37627625 PMC: 10451719. DOI: 10.3390/antiox12081630.


Response of the Glutathione (GSH) Antioxidant Defense System to Oxidative Injury in Necrotizing Enterocolitis.

Golubkova A, Leiva T, Snyder K, Schlegel C, Bonvicino S, Agbaga M Antioxidants (Basel). 2023; 12(7).

PMID: 37507924 PMC: 10376622. DOI: 10.3390/antiox12071385.


Exploring the Diet-Gut Microbiota-Epigenetics Crosstalk Relevant to Neonatal Diabetes.

Alsharairi N Genes (Basel). 2023; 14(5).

PMID: 37239377 PMC: 10218220. DOI: 10.3390/genes14051017.

References
1.
Galea I . The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021; 18(11):2489-2501. PMC: 8481764. DOI: 10.1038/s41423-021-00757-x. View

2.
Zhang P, Lavoie P, Lacaze-Masmonteil T, Rhainds M, Marc I . Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review. Pediatrics. 2014; 134(1):120-34. DOI: 10.1542/peds.2014-0459. View

3.
Mates J, Perez-Gomez C, Nunez de Castro I . Antioxidant enzymes and human diseases. Clin Biochem. 2000; 32(8):595-603. DOI: 10.1016/s0009-9120(99)00075-2. View

4.
Culley M, Chan S . Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018; 128(9):3704-3715. PMC: 6118596. DOI: 10.1172/JCI120847. View

5.
Raffay T, Martin R, Reynolds J . Can nitric oxide-based therapy prevent bronchopulmonary dysplasia?. Clin Perinatol. 2012; 39(3):613-38. PMC: 3437658. DOI: 10.1016/j.clp.2012.06.011. View